| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.005 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.005 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.19 | 0.006 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.006 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.006 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.007 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.082 | 0.008 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.009 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |